Filing Details

Accession Number:
0000899243-19-007350
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-12 19:15:03
Reporting Period:
2019-03-11
Accepted Time:
2019-03-12 19:15:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346302 Xeris Pharmaceuticals Inc XERS Pharmaceutical Preparations (2834) 203352427
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1531178 R Paul Edick C/O Xeris Pharmaceuticals, Inc.
180 N. Lasalle Street, Suite 1600
Chicago IL 60601
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-03-11 30,000 $9.12 155,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,430 Indirect By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018
Footnotes
  1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.98 to $9.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
  2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.